{
    "symbol": "AIH",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-17 10:53:09",
    "content": " In the first half of 2022, total revenue increased 10.6% year-on-year to RMB338.6 million, primarily driven by the sales of the newly introduced fillers and equipment, such as bio-stimulating filler Ellans\u00c3\u00a9, high-end hyaluronic acid filler Juv\u00c3\u00a9derm Voluma and body contouring equipment CoolSculpting 2.0. Excluding the impact of the operations treatment centers which were divested or ceased operations in 2021, revenue from the non-surgical aesthetic medical services in retained services -- in retained treatment centers increased by 86.9% year-on-year. Selling expense were RMB 111.7 million, representing 33.0% of the company's total revenue in the first half of 2022. In terms of operating performance, despite the decrease in the number of treatment centers and mandatory suspension of operations of several treatment centers due to the pandemic preventative measures in the first half of 2022. For the number of treatments, despite a decrease in the number of treatment centers and mandatory suspension of operations of several treatment centers due to the pandemic preventative requirements in the first half of 2022, the company recorded an increase in the number of treatments of 30.2% year-on-year and the number of treatments in routine treatment centers increased by 68.1% year-on-year."
}